A phase II double-blind placebo-controlled randomized study of GDC- 0941 or GDC-0980 with Fulvestrant versus Fulvestrant in advanced or metastatic breast cancer in patients resistant to aromatase inhibitor therapy
Phase of Trial: Phase II
Latest Information Update: 09 Jul 2016
At a glance
- Drugs Apitolisib (Primary) ; Pictrelisib (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms FERGI
- Sponsors Genentech
- 07 Jun 2017 Biomarkers information updated
- 01 Jul 2016 Status changed from active, no longer recruiting to completed.
- 17 Jun 2016 The trial was completed in Hungary (end date:2016-04-07).